ADMS Adamas Pharmaceuticals Inc.

6.42
+0.14  (+2%)
Previous Close 6.28
Open 6.34
Price To Book 4.17
Market Cap 178,290,558
Shares 27,771,115
Volume 302,908
Short Ratio
Av. Daily Volume 329,213

NewsSee all news

  1. Edited Transcript of ADMS earnings conference call or presentation 8-Aug-19 8:30pm GMT
  2. Adamas Announces New Employment Inducement Grant
  3. Adamas Pharmaceuticals Inc (ADMS) Q2 2019 Earnings Call Transcript
  4. Adamas Reports Second Quarter 2019 Financial Results
  5. Need To Know: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Insiders Have Been Selling Shares

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Further development deferred - noted May 9, 2019.
ADS-4101
Partial onset seizures in patents with epilepsy
Phase 3 data due 4Q 2019.
GOCOVRI (amantadine)
Multiple sclerosis (MS)
Approved December, 24 2014.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
Approval announced August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia
Phase 3 open-label data released April 19, 2018.
GOCOVRI (amantadine)
Dyskinesia patients with Parkinson's disease

Latest News

  1. Edited Transcript of ADMS earnings conference call or presentation 8-Aug-19 8:30pm GMT
  2. Adamas Announces New Employment Inducement Grant
  3. Adamas Pharmaceuticals Inc (ADMS) Q2 2019 Earnings Call Transcript
  4. Adamas Reports Second Quarter 2019 Financial Results
  5. Need To Know: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Insiders Have Been Selling Shares
  6. Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  7. What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
  8. Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
  9. Top Ranked Momentum Stocks to Buy for July 8th
  10. Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
  11. Hedge Funds Are Dumping Adamas Pharmaceuticals Inc (ADMS)
  12. INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
  13. Lifshitz & Miller LLP Announces Investigation of Adamas Pharmaceuticals, Inc., ASGN Incorporated, Box, Inc., ChinaCache International Holdings Ltd, Mammoth Energy Services, Inc., Realogy Holdings Corp., Total System Services, Inc., and Verint Systems Inc.
  14. IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
  15. Will Adamas Pharmaceuticals Continue to Surge Higher?
  16. Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%
  17. Should You Worry About Adamas Pharmaceuticals, Inc.'s (NASDAQ:ADMS) CEO Salary Level?
  18. Allergan (AGN) in Focus: Stock Moves 6.2% Higher
  19. The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut